Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma

NCT01035463 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT01035463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01035463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Lead sponsor
University of Nebraska
Phase
Phase 1/2
Overall status
Completed
Start date
November 12, 2009
Completion date
July 27, 2018
Enrollment
74 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-negative, recurrent anaplastic large cell lymphoma, recurrent mantle cell lymphoma, recurrent mature t- and nk-cell non-hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent transformed non-hodgkin lymphoma